April 1, 2024
On Target Laboratories Founder Philip Low Receives Legacy Award from the American Lung Association
Read More January 3, 2024On Target Laboratories Names Scott Huennekens as Executive Chairperson of the Board
Read More November 16, 2023On Target Laboratories Secures $30 Million for Commercialization of CYTALUX® (pafolacianine) injection
Read More August 10, 2023On Target Laboratories Granted New Technology Add-On Payment (NTAP) for CYTALUX® (pafolacianine) injection in Ovarian and Lung Cancer Indications
Read More June 6, 2023CMS Issues Two New ICD-10 PCS Codes for CYTALUX® (pafolacianine) injection
Read More April 11, 2023On Target Laboratories Names Ben Lundgren as Chief Executive Officer
Read More March 27, 2023On Target Laboratories Announces Publication in Journal of Thoracic and Cardiovascular Surgery Phase 3 ELUCIDATE Trial of CYTALUX® (pafolacianine) Injection for Intraoperative Imaging of Lung Cancer
Read More December 16, 2022On Target Laboratories Announces Expanded Indication of CYTALUX® (pafolacianine) injection for Detection of Lung Cancer During Surgery
Read More September 12, 2022On Target Laboratories Announces Publication in Journal of Clinical Oncology of Results from Phase 3 Trial of CYTALUX® (pafolacianine) Injection for Intraoperative Imaging of Ovarian Cancer
Read More July 26, 2022On Target Laboratories and Mauna Kea Technologies Further Explore Targeted Detection and Real-Time Diagnosis of Lung Cancer with a Molecular Imaging Agent
Read More May 18, 2022On Target Laboratories and Mauna Kea Technologies Demonstrate Intraprocedural Targeted Detection of Lung Cancer with a Molecular Imaging Agent
Read More May 11, 2022On Target Laboratories, Inc. Announces Presentation of the Results from the ELUCIDATE Phase 3 Trial for CYTALUX™ (pafolacianine) injection for Intraoperative Molecular Imaging of Lung Cancer
Read More March 8, 2022On Target Laboratories and Mauna Kea Technologies Announce a Novel Clinical Research and Product Development Collaboration
Read More January 13, 2022On Target Laboratories Completes ELUCIDATE Phase 3 Clinical Trial Investigating the Use of CYTALUX™ (pafolacianine) injection in Cancer in the Lung
Read More November 29, 2021On Target Laboratories Announces FDA Approval of CYTALUX™ (pafolacianine) injection for Identification of Ovarian Cancer During Surgery
Read More May 20, 2021On Target Laboratories, Inc. Announces Results of Phase 3 Trial for Pafolacianine for Intraoperative Illumination of Folate Receptor Positive Ovarian Cancer
Read More March 24, 2021On Target Laboratories Secures $21 Million for Development and Commercialization of Pafolacianine Sodium Injection
Read More March 3, 2021On Target Laboratories Announces U.S. FDA Acceptance and Priority Review of New Drug Application for pafolacianine sodium injection for Identification of Ovarian Cancer During Surgery
Read More December 3, 2020On Target Laboratories Announces the Appointment of Tommy Lee as Vice President, Clinical Operations
Read More October 1, 2020On Target Laboratories Announces the Appointment of Patrick Spangler as Chief Financial Officer
Read More July 8, 2020First Patient Enrolled in the Phase 3 ELUCIDATE Trial of Pafolacianine Sodium (formerly OTL38) in the Intraoperative Identification of Lung Cancer Lesions
Read More January 27, 2020Intraoperative Molecular Imaging of Non-Small Cell Lung Cancer Improves Outcomes for 26 Percent of Patients in Multi-Institutional Phase 2 Clinical Trial
Read More October 15, 2019Positive Phase 2 Study Results Published for On Target's Intraoperative Cancer Imaging Agent.
Read More August 19, 2019On Target Completes OTL38 Phase 2 Clinical Trial in Lung Cancer
Read More August 12, 2019On Target Laboratories Appoints Chief Executive Officer
Read More October 15, 2018On Target Laboratories Announces Publication Supporting Use of OTL78 to Highlight Prostate Cancer Lesions
Read More November 3, 2017On Target Laboratories Raises Additional Capital from H.I.G. BioHealth Partners, Elevate Ventures and Helsinn
Read More
Brand Strategy By
Assembly
Developed By
Alchemy + Aim